The Protocol Review and Monitoring System (PRMS) was implemented in 1990 to oversee research involving cancer patients in the facilifies of the institutions that define KCI. The main objectives of the PRMS include the following: 1) review the scientific merit of cancer research protocols;2) ensure prioritizafion of therapeufic cancer protocols according to KCI's scientific priorities;and 3) monitor scienfific proqress. The Protocol Review and Monitoring Committee is composed of a complementary mix of senior and junior investigators from various disciplines, and specialfies, as well as representatives from the Biostatistics Core, nursing and physician extenders, and administrafive support staff from the Clinical Trials Office Core. The members of the committee represent a sufficient size, and breadth of expertise to conduct a critical, fair scienfific review of all clinical research protocols involving cancer patients in the institufions comprising the Cancer Center. The PRMS provides internal oversight of the scientific and research aspects of the cancer trials, in addition to assuring that its clinical resources are engaged to ensure the best practices for scientific endeavors and applicafions. The function of the PRMS is complementary to that ofthe WSU Human Investigations Committee (HIC), which focuses on the protecfion of human subjects. The PRMS is not intended to duplicate or overiap the responsibilifies of the WSU HIC, nor is it intended to perform an audifing or data and safety monitoring function. The PRMS evaluates all cancer clinical trials, whether derived and supported from institutional resources or from industry. However, the PRMS does not duplicate the results of traditional peer review, which includes protocols supported by various NIH mechanisms (e.g., ROIs, UOIs, POIs, UIOs and P50s), and clinical research protocols approved by the NCI's Cancer Therapy Evaluafion Program. Scientific review takes into account the specific rationale, study design, duplication of studies already in progress elsewhere and at the Cancer Center, adequacy of biostafistical input, and feasibility for complefion of the study within a reasonable time frame.
The PRMS provides internal oversight of the scientific aspects of clinical trials at KCI, closely monitoring the scientific merit, scientific priorities, and the scientific progress of KCI's clinical research. The PRMS complements the functions of the IRB, which focuses on protection of human subjects at KCI. Protocols approved by the PRMS for activation are submitted to the IRB for further review.
|Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58|
|Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703|
|Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454|
|Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920|
|Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642|
|Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248|
|Beebe-Dimmer, Jennifer L; Albrecht, Terrance L; Baird, Tara E et al. (2018) The Detroit Research on Cancer Survivors (ROCS) Pilot Study: A focus on outcomes after cancer in a racially-diverse patient population. Cancer Epidemiol Biomarkers Prev :|
|Ahmed, Zainab Sabry Othman; Li, Xin; Li, Feng et al. (2018) Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells. J Cell Biochem 119:9006-9016|
|Desai, Pinkal; Wallace, Robert; Anderson, Matthew L et al. (2018) An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort. Cancer Med 7:2121-2130|
|White, Donna L; Hoogeveen, Ron C; Chen, Liang et al. (2018) A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med 7:2180-2191|
Showing the most recent 10 out of 826 publications